Done Health 高管因非 ADHD 适应症开具兴奋剂获刑:Carlat 播客复盘
ADHD Undone: The Corporate Practice of Medicine
Carlat 精神心理临床播客复盘 Done Health 案:在 ADHD 之外开具兴奋剂并不违法,但该公司 CEO Ruthia He 与首席医师 David Brody 仍被联邦探员逮捕,He 因被认定有潜逃风险直接入狱。节目指出 Done 曾向无童年 ADHD 病史的成人开出数百万粒 Adderall,2022 年洛杉矶一名物质使用障碍患者仍获处方,后死于阿片与可卡因过量。
正文 · 原文
Prescribing stimulants outside of ADHD is not illegal, but what Done did sent the clinical leader to jail. We look at what went wrong and what the charges were, and end with a research update that improves access to psychiatric care the honest way.
CHRIS AIKEN: Prescribing stimulants outside of ADHD is not illegal, so why is the psychiatrist who ran Done Health behind bars? Welcome to the Carlat Psychiatry Podcast, keeping psychiatry honest since 2003. I’m Chris Aiken, the editor-in-chief of the Carlat Report.
KELLIE AIKEN: And I’m Kellie Aiken, a psychiatric NP and a dedicated reader of every issue. It’s the final days of the Done empire. Pharmacies are refusing their scripts. The C-suite is deleting emails and shredding documents. And federal agents are chasing Ruthia He as she tries to flee the country. Stay with us to the end, where our research update points to a more ethical way to ease access to care. Here's the CME quiz for that study:
1. In a 2026 study, how did a community clinic reduce wait times for new psychiatric appointments from 10 months to 6 weeks?
A. Triaging patients through online screening
B. Triaging patients through an interview with a social worker
C. Offering regular times for primary care consultation
D. Reserving time slots for emergencies and hospital discharges
We pick up on this story at the end of 2022. Done has given millions of Adderall pills to adults who didn’t have ADHD in childhood. The supply chain has hit a breaking point, and patients can't get stimulants at the pharmacy, whether prescribed by Done or not. But as the problems stacked up, Done stayed on the defensive. In their view, the government was to blame. People with ADHD had real problems, and most doctors cared more about protecting their own license than about helping them. It was all stigma, and Done was fighting it. Chief physician David Brody took to the blogosphere like a crusader, ranting in boldface and all caps. For Brody, medical professionals who tried to rein in ADHD diagnoses were "reprehensible." Only journalists who wrote for an unintelligent readership would dare to criticize the medical judgment of Done. He actually wrote this in his Done blogs. They are no longer online, but we dug them up through the Wayback Machine. They show how physician arrogance can cloud judgment.
CHRIS AIKEN: Like this. In one post, Brody says that amphetamine withdrawal is benign, as he lashes out at newspapers who wrote that Done was causing withdrawal problems. But when he’s attacking the government for restricting refills, he calls amphetamine withdrawal a dangerous syndrome, one that causes depression, severe stress, and would push patients to use street drugs or even to suicide. On one point, though, he never wavered: ADHD goes badly undertreated, and easing access to stimulants was the only humane fix. Our job isn't to believe in medications. It's to weigh their risks against their benefits. As William Osler put it, "Poisons and medicine are oftentimes the same substance given with different intents." In August 2022, that poison caused a death. In Los Angeles, a man with a substance use disorder started treatment at Done. A review of his controlled substance database showed a clear history of problems, but Done prescribed him Adderall anyway. His addiction worsened, and he died of an opioid and cocaine overdose.
KELLIE AIKEN: Stimulants aren’t as dangerous to combine with opioids as benzodiazepines are, but they still increase the risk of opioid overdose. They don't suppress respiration, but they can trigger more substance use in some people.
CHRIS AIKEN: On the whole, that’s true, but to be fair, there’s also evidence that stimulants reduce the risk of opioid overdose when they are carefully prescribed as part of an MAT program along with a med like Suboxone, probably because they help patients stay on Suboxone. But that wasn’t the scenario with this case at Done.
KELLIE AIKEN:
As the DOJ investigation intensified, Done's CEO Ruthia He knew her time was short. In February 2023, she booked a one-way ticket to Hong Kong, but federal investigators stopped her on the way to the airport. Hoping to win public sympathy, she livestreamed the encounter on Facebook. Undeterred, the investigators seized her phone and forced her to surrender her passport. And what they found on her phone took the investigation to a new level. Hu had been funneling Done's profits into overseas bank accounts, and researching countries that don’t have extradition agreements with the US so she could flee the country without risking arrest. CHRIS AIKEN: KELLIE AIKEN: CHRIS AIKEN:
KELLIE AIKEN: Wait. That sounds like what goes on in plenty of corporate medical practices. I've heard NPs complain that their CEOs pressure them to prescribe esketamine, and keep patients on it long term, because esketamine carries some of the most lucrative CPT codes around. How is that not the same thing?
CHRIS AIKEN:
Most states have loopholes, or don’t put much muscle into the enforcement. One way the corporations get away with it is by creating a straw-man governance, where the company is nominally owned by a physician who lends their name to the project, but the real decisions are made by the MBAs. But as the harms to the public become more real, states are starting to crack down on those arrangements. KELLIE AIKEN: CHRIS AIKEN: KELLIE AIKEN: CHRIS AIKEN:
KELLIE AIKEN: Done may have used the wrong tactics, but they had a good mission: to lower the obstacles that keep people from treatment. Today’s study tried to do that the honest way, and they did: Lowering the average wait time for a new psychiatric appointment from 10 months to 6 weeks. It comes from Giuseppe Guaiana and colleagues, published in *Community Mental Health Journal. They measured a quality improvement initiative out of a Canadian community health center.
CHRIS AIKEN:
Here's how they did it. Instead of booking every new referral for a full hour, they brought in a social worker to sort incoming cases by phone. If the patient had simple questions — like they needed a medication adjustment and had a clear diagnosis with no suicidality — they got a brief appointment by phone the psychiatrist and the referring physician instead of a full assessment. On average, their problems were solved in 10 minute by phone, and that freed up needed time for the other cases. More complex cases got a full visit, which lasted 60 to 90 minutes. KELLIE AIKEN: CHRIS AIKEN:
KELLIE AIKEN: Patients are already sensitive to rejection, and when we tell them they have to wait months to see us, they feel even more like they don’t matter. If the wait time is long in your community, try something to improve it – maybe reserving urgent spots for suicidal patients or people who just came out of the hospital or the ED. Maybe briefer visits for simple questions like they did here. But maybe not refilling industrial amphetamine scripts without ever seeing the patient – that is so… Done. Here’s what you’ll find inside the September issue of the Carlat Report. We scrutinize a newly approved antipsychotic, Bysanti; updates on GLP-1 agonists in psychiatry; and, just in time for autumn equinox, an interview with Norman Rosenthal, who discovered light therapy for seasonal affective disorder. Get $30 off your first year’s subscription with the promo code PODCAST.
来源:Carlat · 精神心理临床解读 · thecarlatreport.com